GSK-205832

Study Sponsor: GSK

Study Title

A Phase IIb, 24 week, randomized, double-blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once-daily via a dry powder inhaler, versus placebo, in participants with asthma

Medicine or Vaccine (generic name)

fluticasone furoate/vilanterol/umeclidinium bromide

Sponsor Identification Number

205832

Trial Registry Identification Number(#'s)

NCT03012061 2016-002843-40

Medical Condition

Asthma

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=205832

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03012061

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2016-002843-40

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

July 2020